A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor
Anna C. Pavlick(Cornell University), Franco M. Muggia(NYU Langone Health), Joan Sorich, Leonard Liebes(New York University), James L. Speyer(Breast Center), Catherine Chodkiewicz(Columbia University Irving Medical Center), Carolyn Wasserheit(Columbia University Irving Medical Center), Zo Phillips(Columbia University Irving Medical Center), Anne Hamilton(Royal Women's Hospital), Andrea Downey(University of New Mexico), Howard S. Höchster(Rutgers, The State University of New Jersey)
Cited by 12
Related Papers
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
|Journal of Clinical Oncology|1997|652